Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma.

Int J Gynecol Cancer

*UCL Cancer Institute and UCL Hospitals, London UK; †Hartford Hospital, Hartford, CT; ‡University of Louisville School of Medicine, Louisville, KY; §IRCCS San Raffaele Hospital, Milan, Italy; ∥The Prince of Wales Hospital Randwick, New South Wales, Australia; ¶Gynecologic Oncology Center, Kiel, Germany; #Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark; **Seoul National University College of Medicine, Seoul, Korea; ††Paris Descartes University, Cochin-Hôtel Dieu, Paris; ‡‡Princess Margaret Hospital, Toronto, Canada; and §§MD Anderson Cancer Centre, Houston, TX.

Published: November 2014

Mucinous carcinomas of the ovary can be primary or metastatic in origin. Improvements in the pathological diagnosis have increased the ability to distinguish between primary and metastatic ovarian cancers and shown that primary mucinous carcinomas are a rare subtype of ovarian cancer. Most tumors are diagnosed at an early stage, and the prognosis after surgery is good. Advanced or recurrent mucinous carcinoma of the ovary responds poorly to current cytotoxic treatments, and the prognosis is poor. Here, we review the guidelines for surgery and the results of treatment of advanced and recurrent disease. Chemotherapy with platinum and paclitaxel is currently used to treat advanced disease, but the effect of these drugs is modest, and new treatments are needed.

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000296DOI Listing

Publication Analysis

Top Keywords

mucinous carcinomas
8
primary metastatic
8
advanced recurrent
8
gynecologic cancer
4
cancer intergroup
4
intergroup gcig
4
gcig consensus
4
consensus review
4
mucinous
4
review mucinous
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!